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Quantification of cancer risk in
glomerulonephritis
James Goya Heaf1* , Alastair Hansen2 and Gunnar Hellmund Laier3
Abstract
Background: The association of increased cancer risk with glomerulonephritis (GN) is well known, but controversy
exists concerning which types of GN are involved, and the size of the association. A national registry survey was
performed to assess the size of this association, and the temporal relationship of cancer diagnosis to GN diagnosis.
Methods: All patients with biopsy-proven GN between 1985 and 2015 in Denmark were extracted from The Danish
Renal Biopsy Registry and the National Pathology Data Bank. Incident cancer diagnoses between 10 years previous
and 10 years subsequent to the GN diagnosis were extracted from the Danish Cancer Registry. Residence, birth and
death data were obtained from the National Patient Register. Expected cancer incidence, classified according to cohort,
age and sex were extracted from the Nordcan database.
Results: Nine hundred eleven cancers were diagnosed in 5594 patients. Thirty five percent were prevalent at renal biopsy.
Prevalence at biopsy was 5.5% (expected 3.1%), but incidence was not increased < 1 year before biopsy. Increased cancer
rates were seen for GN forms: minimal change, endocapillary, focal segmental glomerulosclerosis, mesangioproliferative,
membranous, focal segmental, membranoproliferative, proliferative, ANCA-associated vasculitis, lupus nephritis and
unclassified. Increased cancer rates were seen for lung, prostate, renal, non-Hodgkin lymphoma, myeloma, leukaemia
and skin. The increased incidence was mainly limited to − 1 to 1 year after biopsy, but skin cancer showed an increased
risk over time. Some diagnoses showed an increase 5–10 years after biopsy. Incidence was raised for patients
with uraemia and nephrosis, but less for proteinuria or haematuria. Cancers in patients < 45 years were rare. The
risk of developing cancer 0–3 years after biopsy for patients 45–64 years varied from 7.3% (minimal change) to
15.8% (unclassified GN); > 64 years from 11.8 (endocapillary GN) to 20.3% (unclassified). The diagnosis with the
highest risk was membranoproliferative GN (8.6 & 19.6%).
Conclusions: Cancer rates are increased for many cancer and most GN diagnoses. Cancer screening for patients
< 45 years and for patients without nephrosis or uraemia may not be necessary. The findings suggest that screening
programs for specific GN diagnoses can be extended to other GN forms.
Keywords: Cancer, Glomerulonephritis, Epidemiology, Nephrotic syndrome, Uraemia, Proteinuria, Haematuria
Background
The association of cancer with glomerulonephritis (GN) is
well known, being described as early as 1966 [1]. Detailed
reviews of the subject have been published [2–6]. Most
forms of glomerulonephritis have been implicated: min-
imal change disease (MCD), membranous nephropathy
(MN), focal segmental glomerulosclerosis (FSGS), mesan-
gioproliferative GN (MesPGN), membranoproliferative
GN (also known as mesangiocapillary GN) (MPGN), anti-
GBM disease (anti-GBMGN), and ANCA-related vascu-
litis (ANCAV). Similarly, a large number of cancer forms
have been implicated, including lung, colorectal, stomach,
renal, bladder, prostate, gynaecologic, breast, thymoma,
Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and leu-
kaemia. However, most of these associations are based on
small series, with a limited number of cancer cases, which
do not permit statistical analysis. The relationship of MN
to cancer, primarily solid tumours is the best documented,
with a number of large series. A metaanalysis [7] showed a
prevalence of 10%, primarily lung, prostate, haemato-
logical and colorectal.
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Few population-based studies are available. The associ-
ation of proteinuria with increased later cancer risk is
well documented [8–10]. In a Norwegian national study
of 161 patients with MN between 1988 and 2003 [11],
the cancer incidence after biopsy was 2.4%/year, 2.25
times the expected rate. Follow-up for 15 years did not
seem to show a declining incidence. The largest
population-based study was a Danish national study of
all GN forms for the years 1985–96 [12]. This revealed
102 cancers in 1958 patients during a follow-up period
of average 4.7 years, 1.93 times the expected value. In-
creased rates were seen for MCD, endocapillary GN
(EndGN), MN, MesPGN, and unclassified GN. Cancers
with increased rates were lung, skin, lymphatic and
haematological, non-Hodgkin lymphoma, Hodgkin’s dis-
ease and leukaemia. Haematological malignancy in par-
ticular was 7–17 times more common than expected.
This database has now continued prospectively for
30 years, and permits a detailed study of cancer inci-
dence, with accurate measurement of risk. We decided
to repeat the analysis, with a follow-up period of
10 years. In addition, cancers diagnosed up to 10 years
previous to biopsy were included, allowing prevalence
rates to be assessed.
Methods
All patients with biopsy-proven GN resident in Denmark
between the years 1985–2014 were included. The great
majority of patients were Caucasian.
The study was an observational study in epidemiology
and followed the STROBE guidelines for reporting ob-
servational studies [13].
Renal biopsies
The renal biopsy information was derived from two
registries:
1) Danish Renal Biopsy Registry (DANYBIR). This
registry recorded all biopsies performed in Denmark
between 1985 and 1999 [14]. The reproducibility of
the glomerular diagnosis has been investigated and
found acceptable with a kappa value of 0.61 [15].
2) Since 2000 renal biopsy results have been registered
by the National Pathology Data Bank (Patobank).
The following SNOMED diagnoses were included
(SNOMED codes in parentheses): MCD, (M00100, com-
bined with proteinuria or nephrosis: S65080, S67020, or
S67550), endocapillary GN (EndGN, M46870), FSGS
(M53341), MesPGN (M46862), MN (M68130), MPGN
(M46842), proliferative GN (ProlGN, M46810), focal
segmental proliferative GN (FSPGN, M46811), Focal GN
(M46861), necrotizing and crescentic GN (also known
as extracapillary GN) (NCGN, M46880), unclassified GN
(M40000), anti-GBMGN (S67400), ANCAV (S76950),
lupus nephritis (LN) (S38720). IgA GN was classified
according to the light microscopy diagnosis, mainly
MesPGN. Most cases of EndGN will have been
infection-related GN. For each patient, only one biopsy
was included, being the first biopsy with a GN diagnosis.
Patients less than 15 years old were excluded. For biop-
sies with multiple GN diagnoses, the first mentioned
diagnosis was chosen, with the following exceptions:
anti-GBMGN and ANCAV were given first priority;
MCD and unclassified GN were ignored in the presence
of a more specific diagnosis. The presence in the biopsy
of fibrosis (M49000-M49005) was noted.
Associated clinical diagnoses were registered (vide
infra): Uraemia (SNOMED S65050, S65150, S65110 or
ICD10 N03.x, N18.x), proteinuria (S65080 or N06.x),
haematuria (65,070 or N02.x) and nephrotic syndrome
(S67020, S67500, S67550 or N04.x).
Cancer diagnoses
Using the patient national identity number, these pa-
tients were linked with all registered cancer diagnoses in
the Danish Cancer Registry, which has been in existence
since 1943. ICD-8 diagnoses were converted to the rele-
vant ICD − 10 diagnoses. The following diagnosis groups
were used: colon & rectum (C18.x -C21.x), lung (C26.x-
C34.x), melanoma (C43.x), skin (not melanoma) (C44.x),
breast (C50.0) gynaecologic (C54.x-C57.x), prostate
(C61.x), renal (C64.x-c66.x), bladder (C67.x), Hodgkin
lymphoma (C81.x), non-Hodgkin lymphoma (C82.x-
c88.x), myeloma (C90.x), leukaemia (C91.x-C95.x), un-
classified (all other Cxx.x diagnoses).
All diagnosis groups were incident at first diagnosis
day, thereafter they were regarded as prevalent. “Any”
cancer diagnosis was incident on the first day of the first
cancer diagnosis, and was thereafter prevalent. Thus
“Any cancer” prevalence will usually be less than the
sum of individual cancer prevalences, since multiple
cancers were not included.
Cancer epidemiology
The Danish Cancer Registry exports all cancer data to
the Nordic Cancer database (Nordcan) [16], which pub-
lishes yearly incident and prevalent data, stratified by
diagnosis, 10-year age groups and sex. Data was ex-
tracted for three biopsy cohorts (1985–94, 1995–2004,
2005–2014), based on the results for 1990, 2000, and
2010 respectively.
Patient data
Patient sex and birthday were calculated from the
national identity number. Patients entered the study
10 years before the biopsy and were lost to follow-up
(LTF) 10 years after, unless censored for death or
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emigration. Dates of immigration, emigration and death
were extracted from the National Patient Registry (LPR).
Clinical renal diagnoses (ICD-10 N03.x, N18.x, N02.x,
N04.x, N06.x) were also extracted (vide supra).
Calculations
Observation periods were: 10–5 years, 5–3 years, 3–1 years
and 1–0 years before biopsy; 0–1, 1–3, 3–5, 5–10 years
after biopsy. Analyses of prevalent rates at biopsy used the
observation period 10–0 years before biopsy; overall
cancer incidence − 10 to + 10 years. These observation
periods were derived from the NORDCAN database.
The incidence of cancer increases with age. In order to
measure this, for each year after biopsy, 10% of patients
were assumed to move into the next 10-year age cohort.
For each observation period, the real observation
period was often shorter than the defined, due to immi-
gration, emigration or death. While this effect was
minimal for periods before biopsy, it was substantial for
periods after biopsy, particularly 3–10 years after biopsy,
and was greater in the older age groups. The real aver-
age observation period for the relevant renal diagnosis
and age group (15–44 years; 45–64 years; > 64 years)
was used in calculations.
For incidence rates before biopsy, the rate of (by defin-
ition) survivable cancers was used. Thus, the incidence
rate was measured by changes in prevalence rate.
Number of observed incident cancer episodes per time
interval, and the expected incidence (%/year) were thus
available. The observed incidence (%/yr) was defined as
the number of observed cases divided by the average
observation period. The expected number of cases in the
time interval was defined as expected incidence multi-
plied by the average time period.
Statistics
Statistical analysis was based on observed and expected
cases. Confidence intervals and p-values for indirect
standardized incidence ratios were calculated using the
Poisson model for number of incident cancer cases given
time at risk and population level incidence rates adjusted
for age and calendar year.
Results
The follow-up period was 6.4 ± 3.7 years; for patients
followed for more than 5 years 7.5 ± 0.9 years. Nine
hundred eleven cancers were diagnosed in 5594 patients.
Glomerulonephritis and prevalent cancer
Three hundred thirty (36%) cancers diagnoses were
prevalent at renal biopsy. Patient details and prevalence
at biopsy are shown in Table 1. Prevalence at biopsy was
5.5% (expected 3.1%), but prevalence was only slightly
increased < 1 year before biopsy, where it rose rapidly.
Table 1 Patient age, sex, and cancer prevalence at diagnosis (observed vs. expected)
No.
patients
Age
(yrs)
Female
(%)
Patients with
Cancer
Prevalence
(%)
Expected
prevalence (%)
Risk
Ratio
Minimal change 428 43,3 ± 19 46 19 4,4 1.9 2.4 (1.4–3.7)c
Endocapillary 137 43,4 ± 18 53 7 5,1 1.7 3.0 (1.2–6.2)a
Focal segmental
glomerulosclerosis
408 49,0 ± 17 34 27 6,6 2.7 2.4 (1.6–3.5)c
Mesangioproliferative 1185 42,2 ± 17 36 36 3,0 1.7 1,8 (1.2–2.5)b
Membranous 741 52,3 ± 17 41 37 5,0 3.2 1.5 (1.1–2.1)a
Membranoproliferative 298 49,2 ± 17 50 22 7,4 2.4 3.1 (1.9–4.7)c
Proliferative 113 43,4 ± 19 46 7 6,2 2.1 2.9 (1.2–6.0)a
Focal segmental
proliferative
507 47,3 ± 19 36 15 3,0 2.3 1,3 (0.7–2.1)
Focal 146 56,1 ± 17 41 6 4,1 3.1 1.3 (0.5–1.8)
Crescentic 610 58,4 ± 16 39 27 4,4 3.9 1.1 (0.7–1.6)
Unclassified 552 55,4 ± 18 41 82 14,9 3.0 4.9 (3.9–6.1)c
Anti-GBMGN 92 55,5 ± 22 53 1 1,1 4.4 0.2 (0–1.4)
ANCA associated vasculitis 278 59,1 ± 16 38 21 7,6 4.2 1,8 (1.1–2.5)a
Lupus nephritis
unspecified
99 38,1 ± 17 77 1 1,0 1.5 0,7 (0–3.8)
Lupus nephritis all 422 36.4 ± 15 77 7 1.7 0.7 1.2 (0.5–2.5)
Any 5594 49.4 ± 18 41 330 5.5 3.1 1,8 (1.4–2.1)c
Significant risk ratios in bold type
a:< 0.05; b:< 0.01; c:< 0.001
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Prevalence was raised for most GN diagnoses, with the
exception of FSPGN, Focal GN, NCGN, anti-GBMGN
and LN. Diagnoses with the highest prevalence were:
unclassified, ANCAV, MPGN, FSGS and ProlGN.
Glomerulonephritis and cancer incidence
Incidence rates for GN are shown in Table 2 and Fig. 1.
Incidence was slightly increased up to 1 year before bi-
opsy, but then rose rapidly for the period of − 1 to 1 year,
to a maximum of 2.5%/yr. The increase was related to age
(Fig. 2): < 45 years 0.5%/yr., 45–64 years 2.7%/yr. and > 64
5.6%/yr. This pattern was present for MCD, EndGN,
FSGS, MesPGN, MN, MPGN, ProlGN, LN, ANCAV and
unclassified, but no increase was seen for focal GN,
NCGN, or anti-GBMGN. About 40% of this increase was
prevalent at biopsy, with the exception of MN, where only
20% was present. Incidence then fell, and was no longer
significant at 3–5 years (Fig. 3, pattern a). This pattern
was seen for the diagnoses MCD, EndGN, MPGN and un-
classified. For some GN diagnoses (MesPGN, ProlGN,
FSGS, MN), after an initial fall, an increased incidence
was seen after 5 years (Fig. 3, pattern b). One GN
diagnosis (FSPGN) showed a gradually increasing in-
cidence (pattern C). The presence of fibrosis in the
biopsy (14%) did not affect the cancer incidence.
Ninety nine patients had unspecified lupus as primary
diagnosis. A further 323 patients had lupus as secondary
diagnosis. Their primary diagnoses were MesPGN (38%),
MN (15%), MPGN (13%), ProlGN (9%) FS ProlGN (8%),
End (7%), NCGN (5%) and unclassified (5%). Cancer risk
was increased for all lupus patients combined, primarily
after renal biopsy.
Relationship of cancer type to incidence
Incidence rates for cancer are shown in Table 3. Pattern A
was seen for the following cancer diagnoses (maximum
incidence in %/yr. in brackets): lung (0.3), renal (0.3), non-
Hodgkin lymphoma (0.2), myeloma (0.4), leukaemia
(0.17), prostate (0.7), unclassified (0.5). Renal and unclassi-
fied cancers showed an increased incidence after 5 years.
Unclassified cancers were mostly non-specific, but in-
cluded 10 cases of gastric cancer and 10 cases of pancre-
atic cancer. Non-melanoma skin cancers followed a
different pattern, with an increased incidence throughout
the period of observation, rising from 0.1%/year 10 to 5
years prior to biopsy to 0.7 five to 10 years after (Fig. 3,
pattern c). The late (5–10 years post-biopsy) overall in-
crease in cancer incidence was almost entirely related to
this increase in skin cancers. No increase in incidence was
seen for melanoma, breast, gynaecologic, bladder, or
Hodgkin lymphoma. The incidence of colorectal cancer
was reduced. Other cancers associated with GN in the lit-
erature are shown in Table 4. These cancers were rare, not
permitting statistical analysis.
Relationship of cancer incidence to Nephrological
diagnosis
Clinical data was available was available for 4339 (78%) of
biopsies: uraemia (62%), nephrotic syndrome (30%), pro-
teinuria (15%) and haematuria (6%). Most of the increased
risk was related to the diagnoses uraemia and nephrotic
syndrome. Patients with haematuria had an overall
increase risk (RR 1.5 (1.0–2.2), p < 0.05), but this was
restricted to a late increase (5–10 years RR 3.2 (1.7–5.5),
p < 0.001). Similarly, the overall relationship between
-10 to -5 -5 to -3 -3 to -1 -1 to 0 0 to 1 1 to 3 3 to 5 5 to 10
Interval (years from biopsy)
0,0
0,2
0,4
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2,0
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2,6
2,8
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ecnedicni
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C
*
***
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 Observed
*:p<0.05
**:p<0.01
***:p<0.001
Fig. 1 Observed and expected any cancer incidences for all biopsied
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Table 2 The association of renal diagnosis to observed and expected cancer incidence (%/year) grouped according to time interval
relative to biopsy date
Time interval (years) -10 to −5 −5 to −3 −3 to −1 −1 to 0 0–1 1–3 3–5 5–10 −10 to 10
Minimal
change
Observed 0.19 0.24 0.82 1.40 2.44 1.39 0.64 0.72 0.73
Expected 0.15 0.23 0.31 0.41 0.59 0.64 0.71 0.84 0.45
Risk ratio 1.2
(0.3–3.2)
1.0
(0.1–3.8)
2.6
(1.1–5.4)a
3.4
(1.2–7.4)b
4.1
(2.0–7.6)c
2.2
(1.0–4.0)a
0.9
(0.2–2.3)
0.9
(0.4–1.6)
1.6
(1.2–2.1)c
Endocapillary Observed 0.15 0.36 1.09 1.46 3.32 0.50 1.51 0.29 0.72
Expected 0.14 0.21 0.29 0.39 0.58 0.63 0.71 0.84 0.42
Risk ratio 1.1
(0–6.1)
1.8
(0–9.9)
3.8
(0.8–11.2)a
3.7
(0.4–13.4)
5.8
(1.6–14.7)b
0.8
(0–4.4)
2.1
(0.3–7.7)
0.3
(0–1.9)
1.7
(1.0–2.9)a
Focal segmental
glomerulosclerosis
Observed 0.35 0.74 0.86 1.72 2.08 1.05 0.92 2.10 0.96
Expected 0.20 0.32 0.44 0.57 0.81 0.89 1.00 1.19 0.57
Risk ratio 1.8
(0.7–3.6)
2.3
(0.9–5.1)a
1.9
(0.8–4.0)
3.0
(1.2–6.2)a
2.5
(1.1–5.0)a
1.2
(0.5–2.4)
0.9
(0.3–2.4)
1.8
(0.9–3.0)p = 0.06
1.7
(1.3–2.2)c
Mesangio-
proliferative
Observed 0.17 0.38 0.34 0.76 1.05 0.83 0.97 1.14 0.58
Expected 0.12 0.19 0.26 0.36 0.50 0.56 0.63 0.77 0.38
Risk ratio 1.4
(0.7–2.6)
2.0
(0.9–3.9)a
1.3
(0.6–2.5)
2.1
(1.0–4.1)a
2.1
(1.0–3.8)a
1.5
(0.8–2.5)
1.5
(0.9–2.5)
1.5
(1.0–2.1)a
1.5
(1.2–1.8)c
Membranous Observed 0.30 0.55 0.74 0.94 3.90 1.77 0.93 2.39 1.10
Expected 0.22 0.33 0.47 0.62 0.91 0.99 1.10 1.30 0,65
Risk ratio 1.4
(0.7–2.5)
1.6
(0.7–3.2)
1.6
(0.8–2.9)
1.5
(0.6–3.1)
4.3
(2.8–6.3)c
1.8
(1.1–2.8)a
0.8
(0.4–1.6)
1.8
(1.3–2.6)c
1.7
(1.4–2.0)c
Membrano-
proliferative
Observed 0.48 0.34 0.68 3.04 3.81 2.24 1.45 1.05 1.18
Expected 0.20 0.30 0.42 0.54 0.78 0.85 0.94 1.10 0.55
Risk ratio 2.4
(1.0–4.9)a
1.1
(0.1–4.0)
1.6
(0.4–4.1)
5.6
(2.6–10.6)c
4.9
(2.3–9.0)c
2.6
(1.2–5.0)b
1.5
(0.4–4.0)
1.0
0.4–2.0)
2.2
(1.6–2.8)c
Proliferative Observed 0.53 0 0.88 1.78 1.92 0 0 2.95 0.87
Expected 0.14 0.22 0.31 0.41 0.60 0.66 0.74 0.88 0.43
Risk ratio 3.7
(0.8–10.8)a
0
(0–7.6)
2.9
(0.3–10.4)
4.3
(0.5–15.5)
3.2
(0.4–11.5)
0
(0–3.2)
0
(0–3.5)
3.4
(1.1–7.8)c
2.0
(1.1–3.4)a
Focal segmental
proliferative
Observed 0.16 0.20 0.49 0.79 1.14 1.29 1.50 1.76 0.74
Expected 0.17 0.26 0.36 0.49 0.71 0.78 0.87 1.02 0.52
Risk ratio 0.9
(0.3–2.4)
0.8
(0.1–2.8)
1.4
(0.5–3.2)
1.6
(0.4–4.2)
1.6
(0.5–3.7)
1.7
(0.8–3.0)
1.7
(0.8–3.2)
1.7
(1.1–2.6)a
1.4
(1.1–1.8)b
Focal Observed 0 1.03 0.35 1.37 1.67 0.66 2.48 0.95 0.70
Expected 0.29 0.44 0.61 0.78 1.14 1.23 1.34 1.55 0.75
Risk ratio 0
(0–1.8)
2.3
(0.5–6.9)
0.6
(0–3.3)
1.8
(0.2–6.4)
1.5
(0.2–5.3)
0.5
(0–3.0)
1.9
(0.4–5.4)
0.6
(0.1–1.8)
0.9
(0.5–1.6)
Crescentic Observed 0.23 0.49 0.49 1.31 1.00 1.88 2.49 2.28 0.91
Expected 0.30 0.46 0.64 0.84 1.25 1.34 1.46 1.67 0.79
Risk ratio 0.8
(0.3–1.6)
1.1
(0.4–2.3)
0.8
(0.3–1.9)
1.6
(0.7–3.1)
0.8
(0.3–1.9)
1.4
(0.8–2.4)
1.7
(0.9–2.9)
1.4
(0.8–2.1)
1.2
(0.9–1.4)
Unclassified Observed 0.58 1.09 1.18 7.43 6.71 2.41 1.44 2.10 1.94
Expected 0.28 0.43 0.59 0.77 1.14 1.22 1.33 1.52 0.74
Risk ratio 2.1
(1.2–3.3)a
2.5
(1.3–4.4)b
2.0
(1.1–3.4)a
9.7
(6.9–13.1)c
5,9
(4.0–8.3)c
2,0
(1.2–3.1)b
1.1
(0.4–2.2)
1.4
(0.8–2.3)
2.6
(2.2–3.1)c
Anti-GBM GN Observed 0.00 0.54 0.00 0.00 1.22 3.11 0.00 2.93 0.6
Expected 0.31 0.46 0.62 0.80 1.20 1.26 1.34 1.49 0.7
Risk ratio 0
(0–2.6)
1.2
(0–6.6)
0
(0–3.3)
0
(0–5.1)
1.0
(0–5.7)
2.5
(0.5–7.2)
0
(0–2.8)
2.0
(0.4–5.8)
0.8
(0.4–1.6)
ANCA-associated
vasculitis
Observed 0.50 0.54 1.08 1.80 2.96 1.90 2.43 2.48 1.37
Expected 0.29 0.45 0.62 0.84 1.27 1.36 1.48 1.69 0.84
Risk ratio 1.72
(0.7–3.5)
1.2
(0.2–3.5)
1.7
(0.6–3.8)
2.1
(0.7–5.0)
2.3
(0.9–4.8)
1.4
(0.6–2.9)
1.6
(0.7–3.1)
1.5
(0.8–2.5)
1.6
(1.2–2.1)c
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proteinuria and cancer (RR 1.4 (1.1–1.8) was only appar-
ent after 1 year post-biopsy.
Relationship of specific Glomerulonephritis diagnoses
with cancer diagnosis
Cancer incidence was only slightly increased up to 1 year
prior to biopsy. In order to evaluate the specific relation-
ship between GN and cancer, the number of expected
cases between − 1 to + 10 years after biopsy was sub-
tracted from the observed number. The total number of
excess cases (observed minus expected) was 378. Distribu-
tions of excess cancers by GN and cancer diagnoses are
shown in Tables 5 and 6, along with common associations
in the literature. Considerable differences between ob-
served and previously described associations were seen.
With the exception of skin cancer which showed a gener-
ally increased risk for most cancer types, the number of
cases per diagnosis was too small for statistical analysis,
and clear patterns were not observed.
Assuming that all cancers occurring from 0 to 3 years
after biopsy are diagnosable by invasive means at biopsy,
the expected risk of different cancer forms during this
period, grouped according to GN diagnosis, are shown
in Table 7 and the overall incidence in Fig. 4.
Discussion
The present study is the largest study of the relationship
between GN and cancer, and permits a quantitative as-
sessment of cancer risk for common forms of GN and
cancer, and the temporal relationship between the two
diseases. A further strength is that incidence was com-
pared with the expected age- and sex-adjusted incidence
in the general population. It confirms the increased can-
cer incidence seen in the previous study using this data-
base [12] for MCD, EndGN, MN, MesPGN and
unclassified GN. FSGS, ProlGN FSPGN, ANCAV and
LN ratio were added to the list but no increase was seen
for focal GN, NCGN, or anti-GBMGN. These findings
are in general accord with the literature [2–6]. IgA GN
and Henoch-Schönlein purpura were not specifically
studied in this paper, but most of these patients will have
had MesPGN.
As in the previous study, cancers with increased rates
were lung, skin, non-Hodgkin lymphoma, and leukae-
mia. However increased rates for colorectal cancer and
Hodgkin’s lymphoma could not be confirmed. Myeloma,
renal, prostate and unclassified tumours were added to
the list. These differences may simply due to chance
given the large number of comparisons. Most of these
findings have previously been described. However, the
study does not support previously described relation-
ships to e.g. Hodgkin’s lymphoma [7, 17], colorectal [7]
and gastric cancer [3]. Some of these findings may be
due to a type 2 statistical error due to relative paucity of
the tumours. For instance, the lack of any cases of thym-
oma preclude any contribution to its well-documented
role in GN [18]. Perhaps the most surprising finding is
that non-melanoma skin tumours were the most com-
mon cancer form for several GN diagnoses. Indeed, the
finding is probably an underestimate, in that cancers
were considered prevalent at first diagnosis; most skin
cancers can be expected to be definitively cured shortly
after diagnosis. This observation has received little previ-
ous attention.
About 40% of excess cancers were present at biopsy,
except for MN, where the figure was 20%. This is in ac-
cordance with the metaanalysis of MN by Leeaphorn et
al. [7].
An epidemiological study can contribute little to a
discussion of aetiology. Possible explanations include
cancer causing GN, GN causing cancer due to the
immunosuppressive effects of nephrosis and uraemia,
immunosuppressive effects of GN therapy, or both being
Table 2 The association of renal diagnosis to observed and expected cancer incidence (%/year) grouped according to time interval
relative to biopsy date (Continued)
Time interval (years) -10 to −5 −5 to −3 −3 to −1 −1 to 0 0–1 1–3 3–5 5–10 −10 to 10
Lupus nephritis
unspecified
Observed 0 0 0.51 0 1.14 1.71 2.40 0.75 0.60
Expected 0.10 0.15 0.21 0.28 0.40 0.44 0.49 0.59 0.31
Risk ratio 0
(0–7.9)
0
(0–12.7)
2.4
(0.1–13.6)
0
(0–13.3)
2.9
(0.1–15.9)
3.9
(0.5–14.0)
4.9
(0.6–17.6)
1.3
(0.3–3.7)
1.9
(0.9–3.7)
Lupus nephritis all Observed 0.10 0.24 0.24 0.24 0.78 0.83 0.56 0.89 0.42
Expected 0.09 0.14 0.19 0.25 0.34 0.38 0.43 0.52 0.26
Risk ratio 1.1
(0.1–3.9)
1.7
(0.2–6.3)
1.2
(0.1–4.4)
0.9
(0–5.3)
2.3
(0.5–6.8)
2.2
(0.7–5.2)
1.3
(0.2–4.7)
1.7
(0.9–3.0)
1.6
(1.1–2.3)a
Any Observed 0.28 0.49 0.66 1.83 2.51 1.48 1.34 1.71 0.96
Expected 0.20 0.31 0.43 0.57 0.83 0.90 1.00 1.17 0.58
Risk ratio 1.4
(1.1–1.7)b
1.6
(1.2–2.1)b
1.5
(1.2–1.9)c
3.2
(2.6–3.9)c
3.0
(2.5–3.6)c
1.6
(1.4–2.0)c
1.3
(1.1–1.7)a
1.5
(1.3–1.7)c
1.7
(1.5–1.8)c
Significant risk ratios in bold type
a:< 0.05; b:< 0.01; c:< 0.001
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Fig. 2 Observed and expected any cancer incidences according to age group. a 15–44 years; b 45–64 years; c > 64 years
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Fig. 3 (See legend on next page.)
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caused by a third factor. It is probable that the relation-
ship is partly coincidental: an investigation for cancer
may by chance reveal an undiscovered GN and vice
versa [19]. This possibility is particularly relevant for
renal cancer and myeloma, where renal biopsy may be
included in the routine diagnosis of these diseases.
Implementation of cancer screening for GN, which is
common for MN will have hastened the diagnosis of
subclinical cancers. However, if a renal biopsy resulted
in a major overall shortening of the time to cancer
diagnosis, one would expect that incidence for that
cancer form would fall to below expected for the period
1–3 years after biopsy. Finally, the increased rate may be
due to the carcinogenic effects of GN treatment. How-
ever, the effect of therapy is unlikely to have played a
role in the 36% of cancers that were present at biopsy.
Table 3 The association of cancer diagnosis to observed and expected cancer incidence (%/year) grouped according to time
interval relative to biopsy date
Time interval (years) −10 to −5 −5 to −3 −3 to −1 −1 to 0 0–1 1–3 3–5 5–10 −10 to 10
Colorectal Observed 0.03 0.06 0.05 0.07 0.26 0.06 0.14 0.17 0.08
Expected 0.05 0.09 0.12 0.17 0.22 0.24 0.27 0.33 0.16
Risk ratio 0.5
(0,2–1.0)
0.7
(0.3–1.5)
0.4
(0.2–0.9)b
0.4
(0.1–1.1)
1.2
(0.6–2.1)
0.2
(0.1–0.5)d
0.5
(0.2–1.0)
0.5
(0.3–0.9)c
0.5
(0.4–0.6)d
Lung Observed 0.00 0.03 0.04 0.20 0.32 0.26 0.17 0.23 0.10
Expected 0.01 0.01 0.02 0.06 0.12 0.13 0.14 0.16 0.06
Risk ratio 0.7
(0–3.9)
2.8
(0.6–8.2)
1.8
(0.5–4.6)
3.1
(1.6–5.6)c
2.7
(1.5–4.4)d
2.0
(1.2–3.1)c
1.2
(0.6–2.3)
1.4
(0.9–2.1)
1.6
(1.3–2.0)d
Melanoma Observed 0.01 0.03 0.01 0.04 0.02 0.07 0.07 0.08 0.03
Expected 0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.04 0.03
Risk ratio 0.7
(0.2–2.1)
1.3
(0.3–3.7)
0.3
(0–1.8)
1.1
(0.1–3.9)
0.6
(0–3.4)
2.3
(0.8–5.0)
2.1
(0.6–5.5)
2.1
(0.9–4.4)
1.2
(0.8–1.7)
Breasta Observed 0.13 0.11 0.11 0.22 0.19 0.12 0.03 0.28 0.15
Expected 0.09 0.12 0.17 0.18 0.18 0.19 0.20 0.22 0.15
Risk ratio 1.4
(0.8–2.3)
0.9
(0.3–2.0)
0.6
(0.2–1.5)
1.2
(0.4–2.8)
1.0
(0.3–2.7)
0.6
(0.2–1.6)
0.1
(0–0.8)b
1.2
(0.7–2.0)
1.0
(0.7–1.3)
Gynaecologica Observed 0.02 0.02 0.09 0.13 0.05 0.03 0.09 0.05 0.05
Expected 0.04 0.05 0.06 0.07 0.09 0.09 0.10 0.11 0.07
Risk ratio 0.4
(0.1–1.5)
0.4
(0–2.5)
1.4
(0.4–3.6)
1.7
(0.4–5.1)
0.5
(0–3.0)
0.4
(0–2.1)
1.0
(0.2–2.8)
0.5
(0.1–1.2)
0.7
(0.4–1.2)
Prostatea Observed 0.04 0.08 0.12 0.49 0.74 0.22 0.20 0.27 0.19
Expected 0.04 0.09 0.15 0.17 0.18 0.20 0.22 0.27 0.14
Risk ratio 1.1
(0.5–2.3)
0.8
(0.3–1.9)
0.8
(0.4–1.6)
2.9
(1.7–4.8)d
4.2
(2.6–6.5)d
1.1
(0.5–2.0)
0.9
(0.4–1.9)
1.0
(0.6–1.6)
1.3
(1.1–1.7)d
Renal Observed 0.01 0.02 0.03 0.29 0.16 0.03 0 0.05 0.05
Expected 0.004 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01
Risk ratio 2.0
(0.2–7.1)
2.9
(0.3–10.4)
3.0
(0.6–8.6)
21.4
(12.2–34.8)d
9.2
(4.0–18.2)d
1.8
(0.4–5.1)
0
(0–2.4)
2.3
(0.9–4.7)b
4.1
(2.9–3.5)d
Bladder Observed 0.01 0.02 0.03 0 0.02 0.05 0.05 0.09 0.03
Expected 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.05
Risk ratio 0.2
(0–0.9)b
0.6
(0.1–2.0)
0.7
(0.1–1.9)
0
(0–1.3)
0.3
(0–1.8)
0.7
(0.1–2.1)
0.6
(0.1–1.8)
0.9
(0.4–1.9)
0.5
(0.3–0.8)c
Hodgkin lymphoma Observed 0 0.01 0.01 0 0.02 0 0.00 0.01 0.004
Expected 0.002 0.002 0.002 0.003 0.003 0.003 0.003 0.003 0.003
Risk ratio 0
(0–6.7)
3.9
(0.1–21.7)
3.7
(0.1–20.8)
0
(0–25.2)
6.3
(0.2–34.9)
0
(0–13.9)
0
(0–15.8)
3.2
(0.1–17.9)
1.6
(0.4–4.2)
(See figure on previous page.)
Fig. 3 Patterns of observed cancer incidences according to time relationship to biopsy. a Usual pattern, with increase mainly limited to period −1
to 1 year after biopsy; b Increased incidence around biopsy date, with late increase (membranous nephropathy, FSGS, mesangioproliferative GN,
proliferative, focal segmental proliferative GN; c increasing incidence during period of observation (focal segmental proliferative GN, non-
melanoma skin cancer)
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Only five diseases, MesPGN, proliferative, FSGS, FSPGN
and MN showed a late rise in incidence. While FSGS
treatment is rarely carcinogenic, carcinogenic therapy,
e.g. azathioprine and cyclophosphamide is common
in MesPGN, MPGN, anti-GBMGN, lupus GN and
ANCAV. These observations do not exclude the pos-
sibility that initiation of immunosuppressive therapy
might cause the rapid progression of an already
present sub-clinical cancer to clinical disease during
the first year of treatment. The lack of a major
association between cancer and non-nephrotic pro-
teinuria or haematuria suggests that cancer is mainly
associated with severe renal disease. Similarly, if one
assumes that disease diagnosis time point is associ-
ated with disease severity and/or accelerating activ-
ity, the close temporal conjunction of the cancer and
GN diagnoses suggest that any aetiological common
agent is proportional to disease severity. One can
speculate that the late rise in cancer incidence for
patients with proteinuria and haematuria is thus
Table 3 The association of cancer diagnosis to observed and expected cancer incidence (%/year) grouped according to time
interval relative to biopsy date (Continued)
Time interval (years) −10 to −5 −5 to −3 −3 to −1 −1 to 0 0–1 1–3 3–5 5–10 −10 to 10
Non-Hodgkin
Lymphoma
Observed 0.01 0.02 0.03 0.16 0.17 0.03 0.06 0.06 0.04
Expected 0.01 0.01 0.01 0.02 0.02 0.02 0.03 0.03 0.02
Risk ratio 1.4
(0.3–4.2)
1.5
(0.2–5.5)
1.8
(0.4–5.3)
8.1
(3.7–15.4)d
7.3
(3.1–14.3)d
1.1
(0.1–4.0)
2.3
(0.6–5.9)
1.9
(0.7–4.1)
2.5
(1.8–3.5)d
Myeloma Observed 0.004 0.01 0.02 0.23 0.44 0.02 0 0.02 0.05
Expected 0.001 0.003 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Risk ratio 3.1
(0.1–17.4)
3.0
(0.1–16.8)
3.6
(0.4–12.9)
32.6
(17.3–55.7)d
49.4
(31.0–74.8)d
2.2
(0.3–7.8)
0
(0–4.4)
1.6
(0.3–4.8)
8.6
(6.3–11.6)d
Leukaemia Observed 0.01 0.03 0.06 0.09 0.17 0.03 0.05 0.06 0.04
Expected 0.01 0.02 0.02 0.03 0.04 0.05 0.05 0.06 0.03
Risk ratio 0.8
(0.1–2.8)
1.7
(0.4–5.0)
2.9
(1.2–6.0)b
3.1
(1.0–7.3)b
3.9
(1.7–7.7)c
0.7
(0.1–2.5)
1.0
(0.2–2.8)
0.9
(0.4–1.9)
1.5
(1.0–2.0)b
Skin
(non-melanoma)
Observed 0.08 0.14 0.22 0.21 0.14 0.54 0.64 0.74 0.27
Expected 0.01 0.02 0.03 0.03 0.04 0.04 0.05 0.07 0.03
Risk ratio 7.8
(4.9–11.7)c
7.4
(4.2–12.0)d
8.6
(5.5–12.6)d
6.4
(3.3–11.1)d
3.6
(1.5–7.5)c
12.1
(8.7–16.3)d
12.1
(8.5–16.7)d
10.9
(8.5–13.8)d
8.7
(7.6–9.9)d
Unclassified Observed 0.04 0.05 0.07 0.22 0.53 0.33 0.25 0.43 0.17
Expected 0.04 0.05 0.07 0.11 0.19 0.20 0.22 0.25 0.12
Risk ratio 1.1
(0.6–2.0)
1.1
(0.4–2.4)
1.0
(0.4–2.0)
1.9
(1.0–3.3)b
2.8
(1.9–4.1)d
1.6
(1.1–2.4)b
1.1
(0.7–1.8)
1.7
(1.2–2.3)c
1.5
(1.2–1.7)d
Any not skin Observed 0.20 0.35 0.46 1.63 2.37 0.99 0.77 1.06 0.71
Expected 0.19 0.30 0.41 0.55 0.80 0.86 0.95 1.10 0.55
Risk ratio 1.0
(0.8–1.3)
1.2
(0.8–1.6)
1.1
(0.8–1.5)
2.9
(2.6–3.4)d
3.0
(2.5–3.6)d
1.1
(0.9–1.4)
0.8
(0.6–1.1)
1.0
(0.8–1.1)
1.3
(1.2–1.4)d
Significant risk ratios in bold type
a: relevant sex only. b:< 0.05; c:< 0.01; d:< 0.001
Table 4 Individual cases of other cancers described in the literature as related to GN [3, 4]
Renal Diagnosis Stomach Pancreas Liver Sarcoma Brain Thymus
Minimal Change 0a 0a 1 0a 0a
FSGS 2a 2a 1a 0a 0a
Mesangioproliferative 4 2 2 0a
Membranous 1a 2a 1a 1a 1a
Membranoproliferative 0a 1a 1
Focal segmental proliferative 3 1
Crescentic 1a 1a 0a
Unclassified 4 2
ANCA vasculitis 2
a associations described in the literature
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caused by progression of the renal disease to more
severe forms.
The association of specific cancers to specific GN
diagnoses are shown in Tables 5 and 6. These are at
some variance with the literature. There are well-known
associations between both Hodgkin lymphoma [20] and
thymoma [18] and MCD; this paper cannot contribute
to this discussion due to too few patients. Other well
recognized associations are solid tumours and MN [3],
chronic lymphocytic leukemia and MPGN [21], and
renal cell carcinomas and IgA nephropathy [22]. Possible
aetiological mechanisms for these relationships include
tumour-antibody production against shed tumour anti-
gens (solid tumours and MN) [19]; putative circulating
factor secreted by T lymphocytes, inducing glomerular
cell cytoskeleton degeneration (Hodgkin lymphoma and
MCD) [23]; B-cell production of either a cryoglobulin or
M-component (chronic lymphocytic leukemia and
MPGN) [24]. We found more non-specific relations
between tumour type and GN diagnosis. This is not
entirely unexpected: Lien et al. also found substantial
variation in the linkage between GN form and cancer
type [5]. There are several possible explanations for the
discrepancies. The most common form of cancer was
non-melanoma skin cancer. Since most of these cancers
are cured at diagnosis, previous studies may have missed
these cases. The actual numbers of cancers in each
published series will be small, so considerable variation
in relative incidence must be expected. Even in the
present large study, the number of non-skin cancers per
GN diagnosis only varied between 6 and 33. In contrast
to other studies, where all cases of cancer were
described, Tables 5 and 6 only study the relationship to
excess tumours over and above the expected; this will
tend to reduce the contribution of common cancers. We
suggest therefore that our figures are more accurate than
other studies; however, this question can only be
resolved by a metaanalysis. It may even be possible that
Table 6 Distribution of 378 observed minus expected cases between −1 and 10 years after biopsy according to cancer diagnosis (%)
Cancer Diagnosis Number MCD End FSGS MesPGN MN MPGN FSPGN Focal NCGN Unclassified ANCAV Typical GN in the literature [4]
Lung 37 8 6 16 17 23 11 6 MN, MCD, MPGN,
MesPGN, FSGS, NCGN
Prostate 33 16 20 28 15 8 MCD, NCGN
Renal 30 16 78 NCGN, MesPGN,
MCD, FSGS, MPGN
Non-Hodgkin 22 15 30 36 6 MN, MCD, MPGN,
FSGS, NCGN
Myeloma 37 7 5 17 8 55
Leukemia 15 16 23 10 10 22 19 MN, MCD,
MPGN, FSGS, NCGN
Skin
(non-melanoma)
152 7 6 16 12 8 10 12 11 10 MN
Unclassified 56 11 20 19 5 6 26
Cancer diagnoses with significantly raised incidence only. Negative figures excluded for this analysis. Only figures > 5% shown. MCD: minimal change disease
MN membranous nephropathy, FSGS focal segmental glomerulosclerosis, MesPGN mesangioproliferative GN, MPGN Membranoproliferative GN, FSPGN focal
segmental proliferative GN, NCGN necrotizing and crescentic GN
Fig. 4 Risk of de novo cancer 0–3 years after biopsy by age
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GN has a non-specific carcinogenic effect (or vice versa),
and that previous associations with specific diagnoses
rest upon an overinterpretation of small series. The
practical consequence of these findings is that the
presence of most GN forms should result in a generally
increased non-specific suspicion of cancer.
The distribution of cancers being diagnosed 0–3 years
after renal diagnosis are shown in Table 7 and Fig. 4.
Assuming that most of these cancers can be diagnosed at
biopsy, this table has practical significance. Cancer screen-
ing for MN has received considerable attention. Some
authors [6, 25] recommend extensive screening including
gastroscopy, colonoscopy, gynaecological investigation,
ultrasonic renal scanning and CT thorax, while others do
not advise other than standard age-specific screening in the
absence of specific symptoms or objective findings. The
KDIGO guidelines recommend specific malignancy screen-
ing for MN, FSGS and IgA GN, but not other forms of
GN. The present study suggests that a more general suspi-
cion of cancer should exist for other forms of GN. Patients
under 45 years, and patients without uraemia or nephrotic
syndrome do not appear to need further investigations.
Otherwise measurement of myeloma protein, prostate
specific antigen and a peripheral blood examination should
be standard. An ultrasonic renal scan will usually be
routine in connection with a renal biopsy. A CT thorax
should be performed for smokers. Patients should be in-
formed of an increased skin cancer risk and advised to re-
duce exposure to sun. Regular dermatological assessments
may be beneficial. The present study does not suggest that
there are indications for gastroscopy, coloscopy, gynaeco-
logical investigation or mammography, other than normal
age-specific indications. Whole-body PET-CT or MR scans
can be used for non-Hodgkin lymphoma and other rare
malignancies, primarily for the GN diagnoses MPGN,
MCD and unclassified GN. Figure 4 shows the risk of de
novo cancer diagnoses after renal diagnosis, and can be
used as a guideline for investigational programs.
A number of criticisms to this study can be raised.
The study is limited to a small country, and the results
may not be applicable to other populations. As this was
a registry-based study, important clinical information
was unavailable, such as the presence of HIV, hepatitis C
and concurrent immunosuppressive therapy, which all
lower immune tolerance. Biopsies were evaluated at
different centres by different pathologists; some intra-
and inter-individual differences in diagnoses will have
been unavoidable. IgA nephropathy was not studied
specifically; most of these patients will have been classi-
fied as MesPGN. MPGN is a mixed morphological
category which could contain C3GN, cryoglobulinaemic
GN, and IgA nephropathy. Similarly, LN has a number
of light microscopy patterns. We have attempted to
avoid this issue for LN by providing analyses both for all
LN and for morphological subgroups. No data concern-
ing potentially carcinogenic therapy were available.
These problems document some of the limitations of
registry-based research.
All cancers were assumed to be prevalent at first diag-
nosis, due to the difficulty of differentiating repeat regis-
trations of the same cancer, cancer recurrence and de
novo disease. Thus, the incidence rates presented here
will be an underestimate of the true incidence, particu-
larly for skin tumours (vide supra). While the study
presents probably the largest number of patients and
cancers addressing this question, sub-group analyses still
often contain small numbers of cases, with large confi-
dence intervals, and possibility of type 2 statistical
errors. Similarly, the low incidence of rare tumours
prevents meaningful conclusions for these. However, for
more common forms of cancer, and cancer incidence
generally, the study presents useful information for
guiding physicians in screening practice.
Conclusions
Cancer rates are increased for many cancer and most
GN diagnoses. This study presents the first systematic
quantification of this risk. The increased incidence is
mainly confined to 1 year prior to 1 year after the renal
diagnosis. Some GN diagnoses demonstrate a rise in
cancer 5 years after diagnosis, which may be related to
possible carcinogenic therapy. Most GN forms should
result in a generally increased non-specific suspicion of
cancer. Cancer screening for patients < 45 years and for
patients without nephrosis or uraemia may not be
necessary. This study presents useful information for
guiding physicians in screening practice for common
forms of cancer.
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